Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) and the Technion – Israel institute of technology, announced that their respective subsidiaries have entered into an exclusive worldwide research and license agreement. This agreement aims at the development of a joint project, based on new findings by Nobel Prize laureate Distinguished Professor Aaron Ciechanover, Dr. Gila Maor and Professor Ofer Binah, that can potentially lead to the development of novel anti-cancer drugs. The pre-clinical research was funded thus far by Dr. Alfred Mann.

“We are very excited about this new endeavor between Sun Pharma, with the Technion. We are confident that this  collaboration will help us move rapidly forward with our research” said Ciechanover and Binah. “We explored  several collaboration alternatives, but Sun Pharma’s market leadership and its long term commitment have made this collaboration a very high priority for us”.

“The Technion is delighted to partner with Sun Pharma to advance this project through pre-clinical development  process. This collaboration is an excellent example of interactions between academic discovery and pharmaceutical  companies demonstrating the valuable contribution academic institutions can make in bringing new products to  help patients worldwide. We sincerely believe this agreement represents the beginning of a long and fruitful  relationship between the Technion and Sun Pharma”, added Ciechanover and Binah.

“This collaboration is part of the various initiatives that Sun Pharma is taking to enhance its specialty pipeline.  Mutually beneficial partnerships with independent research institutes, especially world renowned institutes, such as  the Technion, is our preferred route to bring to the market, innovative products for unmet medical needs” said  Kirti Ganorkar, Senior Vice President, Business Development, Sun Pharma.

Sun Pharma is the world’s fifth largest specialty  generic pharmaceutical company and India’s top pharmaceutical company. A vertically integrated business,  economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at  affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150  countries across the world. Sun Pharma’s global presence is supported by 45 manufacturing facilities spread across  5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The  pro forma consolidated revenues for 12 months ending December 2014 are at US$4.5 billion, of which US contributes US$2.2 billion. In India, the company enjoys leadership across 11 different classes of doctors with 31  brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers  over 50 countries and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets with 5 brands enjoying category leadership across India, Romania and Nigeria. Its  API business footprint is strengthened through 11 world class API manufacturing facilities across the globe. Sun  Pharma fosters excellence through innovation supported by strong R&D capabilities comprising 1800 scientists and  R&D investments of 6.3% of annual revenues.

Founded in 1912, Technion – Israel Institute of Technology is the oldest university in Israel. The Technion offers undergraduate and graduate degrees in science and  engineering, and related fields such as architecture, medicine, industrial management and education. It has 18  academic departments and over 50 research centers. Since its founding, it has awarded over 100,000 degrees.  Technion’s over 600 faculty members include three Nobel Laureates. The Technion-Israel Institute of Technology  is a major source of the innovation and brainpower that drives the Israeli economy, and a key to Israel’s reputation as the world’s “Start-Up Nation.” Technion people, ideas and inventions make immeasurable  contributions to the world including life-saving medicine, sustainable energy, computer science, water conservation  and nanotechnology. In December 2011, a bid by Technion with Cornell University won a competition to establish an applied science and engineering institution in New York City; the Jacobs Technion Cornell Institute. In 2013, the  Technion signed with China’s Shantou University (STU) to establish the Technion Guangdong Institute of  Technology in China. T3 – Technion Technology Transfer is the technology transfer arm of the TRDF Ltd. T3 is  responsible for the commercializing of Technion IP.



Thank you for contacting ExitHub. We'll respond as soon as possible.


© 2018 ExitHub Inc. All Rights Reserved.

Log in with your credentials


Forgot your details?

Create Account